Channel Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
0.631
-0.009 (-1.38%)
Dec 24, 2024, 12:16 PM EST - Market open
Channel Therapeutics Employees
As of December 31, 2023, Channel Therapeutics had 8 total employees, including 4 full-time and 4 part-time employees. The number of employees increased by 6 or 300.00% compared to the previous year.
Employees
8
Change (1Y)
6
Growth (1Y)
300.00%
Revenue / Employee
n/a
Profits / Employee
-$1,258,470
Market Cap
3.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Nuwellis | 59 |
| HeartSciences | 15 |
| TNF Pharmaceuticals | 6 |
| 180 Life Sciences | 4 |
| Protagenic Therapeutics | 3 |
| Aptorum Group | 3 |
| Silo Pharma | 3 |
| GT Biopharma | 2 |
CHRO News
- 4 days ago - Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine - GlobeNewsWire
- 6 days ago - Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model - GlobeNewsWire
- 4 weeks ago - Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - GlobeNewsWire
- 2 months ago - Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - GlobeNewsWire
- 2 months ago - Chromocell Announces Amendment to Stock Repurchase Plan - GlobeNewsWire
- 3 months ago - Chromocell to Participate in Life Sciences Investor Forum September 19th - GlobeNewsWire
- 4 months ago - Chromocell Announces Stock Repurchase Plan - GlobeNewsWire
- 5 months ago - Chromocell to Participate in the Virtual Investor Lunch Break Series - GlobeNewsWire